PFIZER INC Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Pfizer Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2010 to Q3 2024.
  • Pfizer Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 29, 2024 was $14.5B, a 30.4% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $14.5B +$3.37B +30.4% Sep 29, 2024 10-Q 2024-11-04
Q2 2024 $11.4B +$1.16B +11.4% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $11B -$1.32B -10.7% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $11.6B +$614M +5.61% Dec 31, 2023 10-Q 2024-11-04
Q3 2023 $11.1B -$4.99B -31% Oct 1, 2023 10-Q 2023-11-08
Q2 2023 $10.2B -$4.92B -32.5% Jul 2, 2023 10-Q 2023-08-09
Q1 2023 $12.3B -$920M -6.96% Apr 2, 2023 10-Q 2023-05-10
Q4 2022 $11B -$527M -4.59% Dec 31, 2022 10-K 2024-02-22
Q3 2022 $16.1B +$4.18B +35.1% Oct 2, 2022 10-Q 2022-11-09
Q2 2022 $15.2B +$4.57B +43.1% Jul 3, 2022 10-Q 2022-08-10
Q1 2022 $13.2B +$3.36B +34.1% Apr 3, 2022 10-Q 2022-05-11
Q4 2021 $11.5B +$3.57B +45.1% Dec 31, 2021 10-K 2023-02-23
Q3 2021 $11.9B +$1.89B +18.8% Oct 3, 2021 10-Q 2021-11-12
Q2 2021 $10.6B +$1.46B +16% Jul 4, 2021 10-Q 2021-08-12
Q1 2021 $9.86B -$17M -0.17% Apr 4, 2021 10-Q 2021-05-13
Q4 2020 $7.91B +$1.14B +16.8% Dec 31, 2020 10-K 2022-02-24
Q3 2020 $10B +$573M +6.07% Sep 27, 2020 10-Q 2020-11-05
Q2 2020 $9.13B -$665M -6.79% Jun 28, 2020 10-Q 2020-08-06
Q1 2020 $9.88B +$282M +2.94% Mar 29, 2020 10-Q 2020-05-07
Q4 2019 $6.77B -$1.25B -15.6% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $9.44B -$585M -5.84% Sep 29, 2019 10-Q 2019-11-07
Q2 2019 $9.79B -$80M -0.81% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $9.6B +$147M +1.56% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $8.03B -$196M -2.38% Dec 31, 2018 10-K 2020-02-27
Q3 2018 $10B +$22M +0.22% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 $9.87B +$397M +4.19% Jul 1, 2018 10-Q 2018-08-09
Q1 2018 $9.45B +$560M +6.3% Apr 1, 2018 10-Q 2018-05-10
Q4 2017 $8.22B -$4M -0.05% Dec 31, 2017 10-K 2019-02-28
Q3 2017 $10B +$166M +1.69% Oct 1, 2017 10-Q 2017-11-09
Q2 2017 $9.48B +$338M +3.7% Jul 2, 2017 10-Q 2017-08-10
Q1 2017 $8.89B -$141M -1.56% Apr 2, 2017 10-Q 2017-05-11
Q4 2016 $8.23B +$49M +0.6% Dec 31, 2016 10-K 2018-02-22
Q3 2016 $9.84B +$301M +3.16% Oct 2, 2016 10-Q 2016-11-10
Q2 2016 $9.14B +$187M +2.09% Jul 3, 2016 10-Q 2016-08-11
Q1 2016 $9.03B +$113M +1.27% Apr 3, 2016 10-Q 2016-05-12
Q4 2015 $8.18B -$225M -2.68% Dec 31, 2015 10-K 2017-02-23
Q3 2015 $9.54B -$420M -4.22% Sep 27, 2015 10-Q 2015-11-05
Q2 2015 $8.95B -$1.44B -13.8% Jun 28, 2015 10-Q 2015-08-06
Q1 2015 $8.92B -$479M -5.1% Mar 29, 2015 10-Q 2015-05-07
Q4 2014 $8.4B -$956M -10.2% Dec 31, 2014 10-K 2016-02-29
Q3 2014 $9.96B -$1.42B -12.5% Sep 28, 2014 10-Q 2014-11-06
Q2 2014 $10.4B -$1.14B -9.85% Jun 29, 2014 10-Q 2014-08-07
Q1 2014 $9.4B -$3.34B -26.2% Mar 30, 2014 10-Q 2014-05-08
Q4 2013 $9.36B -$1.32B -12.3% Dec 31, 2013 10-K 2015-02-27
Q3 2013 $11.4B -$1.15B -9.2% Sep 29, 2013 10-Q 2013-11-08
Q2 2013 $11.5B -$1.36B -10.6% Jun 30, 2013 10-Q 2013-08-09
Q1 2013 $12.7B -$1.45B -10.2% Mar 31, 2013 10-Q 2013-05-10
Q4 2012 $10.7B -$2.38B -18.2% Dec 31, 2012 10-K 2014-02-28
Q3 2012 $12.5B -$3.23B -20.5% Sep 30, 2012 10-Q 2012-11-09
Q2 2012 $12.9B -$2.31B -15.2% Jul 1, 2012 10-Q 2012-08-09
Q1 2012 $14.2B -$1B -6.59% Apr 1, 2012 10-Q 2012-05-10
Q4 2011 $13.1B -$322M -2.41% Dec 31, 2011 10-K 2013-02-28
Q3 2011 $15.7B +$1.45B +10.1% Oct 2, 2011 10-Q 2011-11-10
Q2 2011 $15.2B +$1.18B +8.42% Jul 3, 2011 10-Q 2011-08-11
Q1 2011 $15.2B +$1.57B +11.5% Apr 3, 2011 10-Q 2011-05-12
Q4 2010 $13.4B Dec 31, 2010 10-K 2012-02-28
Q3 2010 $14.3B Oct 3, 2010 10-Q 2010-11-12
Q2 2010 $14B Jul 4, 2010 10-Q 2010-08-12
Q1 2010 $13.6B Apr 4, 2010 10-Q 2010-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.